Evogene Current Ratio 2012-2021 | EVGN

Evogene current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Evogene Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.07B $0.01B 12.74
2021-03-31 $0.07B $0.01B 13.65
2020-12-31 $0.05B $0.01B 5.36
2020-09-30 $0.05B $0.01B 9.79
2020-06-30 $0.04B $0.01B 8.27
2020-03-31 $0.04B $0.00B 9.55
2019-12-31 $0.05B $0.01B 8.53
2019-09-30 $0.05B $0.01B 11.38
2019-06-30 $0.05B $0.01B 10.14
2019-03-31 $0.05B $0.01B 9.88
2018-12-31 $0.06B $0.01B 10.22
2018-09-30 $0.06B $0.01B 11.86
2018-06-30 $0.06B $0.01B 12.96
2018-03-31 $0.07B $0.01B 14.54
2017-12-31 $0.07B $0.01B 15.61
2017-09-30 $0.08B $0.01B 16.70
2017-06-30 $0.08B $0.01B 17.66
2017-03-31 $0.09B $0.01B 15.15
2016-12-31 $0.09B $0.01B 17.13
2016-09-30 $0.10B $0.01B 17.04
2016-06-30 $0.10B $0.01B 18.10
2016-03-31 $0.10B $0.01B 22.20
2015-12-31 $0.10B $0.01B 18.51
2015-09-30 $0.11B $0.01B 22.87
2015-06-30 $0.11B $0.01B 20.37
2015-03-31 $0.12B $0.01B 19.79
2014-12-31 $0.12B $0.01B 14.97
2014-09-30 $0.11B $0.01B 17.85
2014-06-30 $0.11B $0.01B 17.56
2014-03-31 $0.12B $0.01B 17.84
2013-12-31 $0.13B $0.01B 15.12
2013-09-30 $0.05B $0.01B 6.11
2013-06-30 $0.05B $0.01B 5.97
2013-03-31 $0.06B $0.01B 6.77
2012-12-31 $0.06B $0.01B 6.04
2012-09-30 $0.06B $0.01B 7.19
2012-06-30 $0.06B $0.01B 7.15
2012-03-31 $0.06B $0.01B 7.90
2011-12-31 $0.06B $0.01B 6.67
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.069B $0.001B
Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76